Opinion|Videos|April 1, 2025
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Advertisement
Episodes in this series
Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Advertisement
Related to this article
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
5